Who owns ARQT?
Institutional ownership of Arcutis Biotherapeutics Inc. from Form 13F, Q2 2026
272 institutional managers reported holding Arcutis Biotherapeutics Inc. (ARQT) in Form 13F filings for Q2 2026, with 131,436,612 shares worth $3.4B. The largest reported holder was Montanova Capital, LLC. Managers that filed both quarters cut a net 886,060 shares (-0.7%). 40 opened new positions and 34 sold out.
- Funds holding
- 272
- Value held
- $3.4B
- New / sold out
- 40 / 34
- Net shares, same filers
- -0.7%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of ARQT
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Montanova Capital, LLC | $326M | 9.5% | 12,437,000 | Added |
| BlackRock, Inc. | $277M | 8.0% | 10,545,466 | Added |
| Frazier Life Sciences Management, L.P. | $259M | 7.5% | 9,874,511 | Unchanged |
| Rubric Capital Management LP | $217M | 6.3% | 8,271,577 | Unchanged |
| Polar Capital Holdings Plc | $173M | 5.0% | 6,606,945 | Added |
| State Street Corp | $153M | 4.4% | 5,822,840 | Trimmed |
| Vanguard Capital Management LLC | $131M | 3.8% | 4,988,756 | Added |
| Morgan Stanley | $117M | 3.4% | 4,451,014 | Added |
| Jennison Associates LLC | $111M | 3.2% | 4,219,058 | Trimmed |
| D. E. Shaw & Co., Inc. | $104M | 3.0% | 3,949,609 | Added |
| UBS Group AG | $87.4M | 2.5% | 3,333,015 | Added |
| Bank of America Corp | $78.3M | 2.3% | 2,987,431 | Added |
| Geode Capital Management, LLC | $78.2M | 2.3% | 2,982,446 | Trimmed |
| Vanguard Portfolio Management LLC | $63.7M | 1.8% | 2,429,005 | Added |
| Orbimed Advisors LLC | $53.5M | 1.6% | 2,042,000 | New |
| Franklin Resources Inc | $50.6M | 1.5% | 1,930,982 | Trimmed |
| American Century Companies Inc | $50.5M | 1.5% | 1,925,031 | Added |
| Goldman Sachs Group Inc | $43.7M | 1.3% | 1,668,367 | Added |
| Jupiter Topco LLC | $37.0M | 1.1% | 1,410,435 | First report |
| Oberweis Asset Management Inc/ | $36.0M | 1.0% | 1,372,941 | Added |
| Gilder Gagnon Howe & Co LLC | $34.4M | 1.0% | 1,313,211 | Trimmed |
| GW&K Investment Management, LLC | $33.8M | 1.0% | 1,288,018 | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | $33.2M | 1.0% | 1,265,283 | Trimmed |
| Bamco Inc | $32.9M | 1.0% | 1,253,120 | Added |
| Citadel Advisors LLC | $30.4M | 0.9% | 1,160,014 | Added |
Share of 13F holdings is each fund's shares as a share of the 131,436,612 ARQT shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Orbimed Advisors LLC New+$53.5M
- D. E. Shaw & Co., Inc. Added+$38.1M
- BlackRock, Inc. Added+$35.3M
- Citadel Advisors LLC Added+$30.0M
- Jones Hill Capital LP New+$28.6M
- Polar Capital Holdings Plc Added+$24.6M
- Bank of America Corp Added+$20.1M
- Millennium Management LLC Added+$13.5M
- Vanguard Portfolio Management LLC Added+$12.4M
- American Century Companies Inc Added+$12.1M
Biggest sellers in Q2 2026
- Gilder Gagnon Howe & Co LLC Trimmed-$78.4M
- Marshall Wace, LLP Trimmed-$52.0M
- Driehaus Capital Management LLC Trimmed-$35.3M
- Jennison Associates LLC Trimmed-$20.0M
- Stempoint Capital LP Trimmed-$19.1M
- MPM Bioimpact LLC Sold out-$17.3M
- Squarepoint Ops LLC Trimmed-$14.8M
- State Street Corp Trimmed-$12.4M
- Eversept Partners, LP Trimmed-$11.6M
- M&G PLC Sold out-$11.3M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $444M and sold $460M; 95 added and 100 trimmed.
Schedule 13D and 13G filings on ARQT
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by Arcutis Biotherapeutics Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by Arcutis Biotherapeutics Inc.Schedule 13G
- 2026-05-12STATE STREET CORP SCHEDULE 13G filed by Arcutis Biotherapeutics Inc.Schedule 13G
Questions about ARQT ownership
- Who owns ARQT stock?
- 272 institutional investment managers reported ARQT positions in their Form 13F filings for Q2 2026, holding 131,436,612 shares worth $3.4B in total. Montanova Capital, LLC reported the largest position.
- Are funds buying or selling ARQT?
- In Q2 2026, 40 managers opened new ARQT positions, 95 added, 100 trimmed and 34 sold out. Managers that filed in both quarters sold a net 886,060 shares.
- How current is this ARQT institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to ARQT by CUSIP. Options are left out. ARQT news and filings · ARQT insider trades · Top funds